
Hadean Ventures
Overview
Life science fund manager investing in Nordic companies.
Founded
2014
Deals · 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Kasvu Therapeutics | Sep 2026Led | $34 MSeries A | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Step Pharma | Oct 2025Participated | $44 MSeries C | |
ARTHEx Biotech | Sep 2025Participated | $87 MSeries B | |
Actithera | Jul 2025Led | $76 MSeries A | |
SciRhom | Jul 2024Led | $68 MSeries A | |
Complement Therapeutics | Apr 2023Participated | $79 MSeries A | |
Alex Therapeutics | Apr 2022Led | $4 MOther Equity | |
TargED Biopharmaceuticals | Feb 2022Led | $44 MSeries A | |
Ribbon Biolabs | Jan 2022Led | $20 MSeries A | |
Emergence Therapeutics | Dec 2021Participated | $98 MSeries A | |
Cardior Pharmaceuticals | Aug 2021Participated | $75 MSeries B | |
Kasvu Therapeutics | Sep 2026Led | $34 MSeries A | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Step Pharma | Oct 2025Participated | $44 MSeries C | |
ARTHEx Biotech | Sep 2025Participated | $87 MSeries B | |
Actithera | Jul 2025Led | $76 MSeries A | |
SciRhom | Jul 2024Led | $68 MSeries A | |
Complement Therapeutics | Apr 2023Participated | $79 MSeries A | |
Alex Therapeutics | Apr 2022Led | $4 MOther Equity | |
TargED Biopharmaceuticals | Feb 2022Led | $44 MSeries A | |
Ribbon Biolabs | Jan 2022Led | $20 MSeries A | |
Emergence Therapeutics | Dec 2021Participated | $98 MSeries A | |
Cardior Pharmaceuticals | Aug 2021Participated | $75 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 5 | 4 |
| Series B | 1 | 3 |
| Series C+ | 1 | 1 |
| Other Equity | 3 | 3 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 1 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 1 |
| Jan '22 | 1 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 1 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 21 |
| AI & Machine Learning | 2 |
| Space & Frontier Tech | 2 |
| Data, Analytics & IT | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 4 |
| $5M-$10M | 0 |
| $10M-$25M | 2 |
| $25M-$50M | 8 |
| $50M-$100M | 7 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 20 |
| United States | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Bpifrance | 4 |
| Kurma Partners | 4 |
| Sunstone Life Science Ventures | 4 |
| Andera Partners | 3 |
| Fund+ | 3 |
| High-Tech Grunderfonds | 3 |
| INKEF Capital | 3 |
| Pontifax | 3 |
| BioGeneration Ventures | 2 |
| Bristol Myers Squibb | 2 |
| Canica | 2 |
| Curie Capital | 2 |
| Innovestor | 2 |
| Investinor | 2 |
| OrbiMed | 2 |
| Sunstone Capital | 2 |
| Wellington Partners | 2 |
| 4BIO Capital | 1 |
| Adjuvant Capital | 1 |
| Advent France Biotechnology | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 10 | 48% |
| Participating | 11 | 52% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 5 | 50% |
| Co-led | 5 | 50% |
Team
Senior Investment Director
Investment Analyst
Head of Investor Relations
Managing Partner
Partner
Managing Partner